NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $10.38, above its previous 52-week high of $10.35 with 1.4 million shares traded as of 3:35 p.m. ET. Average volume has been 1.1 million shares over the past 30 days.
Akorn has a market cap of $880.6 million and is part of the
industry. Shares are up 65.9% year to date as of the close of trading on Monday.
Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company has a P/E ratio of 15.5, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Akorn as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full
52-week high stocks
or get investment ideas from our